• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding.

作者信息

Yin Emily S, Totonchy Mariam B, Leventhal Jonathan S

机构信息

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.

出版信息

JAAD Case Rep. 2017 Mar 2;3(2):90-92. doi: 10.1016/j.jdcr.2016.10.008. eCollection 2017 Mar.

DOI:10.1016/j.jdcr.2016.10.008
PMID:28280766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5334519/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0afc/5334519/85573f7908ee/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0afc/5334519/b10b8551c0c6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0afc/5334519/9a48ef51e2c6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0afc/5334519/85573f7908ee/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0afc/5334519/b10b8551c0c6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0afc/5334519/9a48ef51e2c6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0afc/5334519/85573f7908ee/gr3.jpg

相似文献

1
Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding.一名急性髓系白血病患者出现与纳武单抗相关的白癜风样色素脱失：一项新发现。
JAAD Case Rep. 2017 Mar 2;3(2):90-92. doi: 10.1016/j.jdcr.2016.10.008. eCollection 2017 Mar.
2
Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.病例报告：非黑色素瘤晚期癌症中与免疫检查点抑制剂相关的白癜风样色素脱失：三例报告及个体患者数据汇总分析
Front Oncol. 2023 Jan 13;12:1099108. doi: 10.3389/fonc.2022.1099108. eCollection 2022.
3
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.免疫相关不良反应与接受抗 PD-1 免疫治疗的转移性黑色素瘤患者的生存改善相关。
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521. doi: 10.1007/s00432-018-2819-x. Epub 2018 Dec 11.
4
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.免疫相关不良事件与非小细胞肺癌的程序性细胞死亡蛋白-1 和程序性死亡配体 1 抑制剂相关：PRISMA 系统评价和荟萃分析。
BMC Cancer. 2019 Jun 10;19(1):558. doi: 10.1186/s12885-019-5701-6.
5
Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.接受抗程序性死亡受体 1 免疫治疗的肺癌患者接种流感疫苗不会引起免疫相关不良事件。
Eur J Cancer. 2018 Nov;104:182-187. doi: 10.1016/j.ejca.2018.09.012. Epub 2018 Oct 24.
6
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.抗PD-1或抗PD-L1免疫疗法诱导的血液学免疫相关不良事件：一项描述性观察研究。
Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.
7
Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report.非小细胞肺癌患者接受帕博利珠单抗治疗后出现白癜风样色素脱失：一例报告
Transl Lung Cancer Res. 2020 Aug;9(4):1585-1590. doi: 10.21037/tlcr-20-386.
8
Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.肿瘤患者接受非黑色素瘤转移性癌症免疫治疗后出现白癜风样脱色。
Clin Exp Dermatol. 2019 Aug;44(6):643-646. doi: 10.1111/ced.13867. Epub 2019 Jan 7.
9
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.免疫相关不良反应预测抗 PD-1 抗体在癌症患者中的治疗效果。
Eur J Cancer. 2019 Mar;109:21-27. doi: 10.1016/j.ejca.2018.10.014. Epub 2019 Jan 22.
10
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.纳武利尤单抗治疗胃癌患者的免疫相关不良事件与预后的相关性。
BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y.

引用本文的文献

1
Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity.癌症治疗相关皮肤毒性：揭示皮肤免疫的窗口
Hematol Oncol Clin North Am. 2024 Oct;38(5):1011-1025. doi: 10.1016/j.hoc.2024.05.002. Epub 2024 Jun 12.
2
Progress of research on PD-1/PD-L1 in leukemia.PD-1/PD-L1 在白血病中研究进展。
Front Immunol. 2023 Sep 26;14:1265299. doi: 10.3389/fimmu.2023.1265299. eCollection 2023.
3
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.

本文引用的文献

1
Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.纳武单抗治疗晚期黑色素瘤患者中白癜风发生与临床获益的相关性：一项多机构回顾性研究。
J Dermatol. 2017 Feb;44(2):117-122. doi: 10.1111/1346-8138.13520. Epub 2016 Aug 11.
2
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.抗PD-1/PD-L1免疫检查点抗体的皮肤并发症
Curr Opin Oncol. 2016 Jul;28(4):254-63. doi: 10.1097/CCO.0000000000000290.
3
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.
免疫检查点抑制剂诱导的皮肤免疫相关不良事件（irAEs）的分子机制。
Curr Oncol. 2023 Jul 18;30(7):6805-6819. doi: 10.3390/curroncol30070498.
4
Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.现代靶向治疗和免疫治疗对皮肤恶性肿瘤患者的皮肤副作用
Cancers (Basel). 2023 Jun 9;15(12):3126. doi: 10.3390/cancers15123126.
5
Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.病例报告：非黑色素瘤晚期癌症中与免疫检查点抑制剂相关的白癜风样色素脱失：三例报告及个体患者数据汇总分析
Front Oncol. 2023 Jan 13;12:1099108. doi: 10.3389/fonc.2022.1099108. eCollection 2022.
6
The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report.抗程序性细胞死亡蛋白-1 治疗对预先存在白癜风的非小细胞肺癌患者色素脱失恶化至恢复的时间窗：1 例病例报告。
Front Immunol. 2022 Aug 16;13:946829. doi: 10.3389/fimmu.2022.946829. eCollection 2022.
7
Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.免疫检查点抑制剂相关的皮肤不良反应：一篇综述文章。
Curr Oncol. 2022 Apr 18;29(4):2871-2886. doi: 10.3390/curroncol29040234.
8
Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study.接受抗程序性细胞死亡蛋白1疗法治疗黑色素瘤患者的肿瘤反应及与白癜风相关的临床因素分析：一项横断面研究。
JAAD Int. 2021 Oct 19;5:112-120. doi: 10.1016/j.jdin.2021.09.002. eCollection 2021 Dec.
9
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.癌症免疫治疗学会（SITC）免疫检查点抑制剂相关不良反应临床实践指南。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002435.
10
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.免疫检查点抑制剂的皮肤不良事件：文献综述
Dermatol Pract Concept. 2021 Jan 29;11(1):e2021155. doi: 10.5826/dpc.1101a155. eCollection 2021 Jan.
抗 PD-1 治疗中的细胞毒性皮肤不良反应。
Clin Cancer Res. 2016 Aug 15;22(16):4023-9. doi: 10.1158/1078-0432.CCR-15-2872. Epub 2016 Mar 8.
4
Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.纳武单抗治疗原发性口腔黏膜黑色素瘤期间银屑病样皮疹的发生情况。
JAMA Dermatol. 2015 Jul;151(7):797-9. doi: 10.1001/jamadermatol.2015.0249.
5
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.接受免疫治疗的 III-IV 期黑色素瘤患者出现白癜风样色素脱失及其与生存的关系：系统评价和荟萃分析。
J Clin Oncol. 2015 Mar 1;33(7):773-81. doi: 10.1200/JCO.2014.57.4756. Epub 2015 Jan 20.
6
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.黑色素细胞和黑色素瘤的表面抗原。黑色素细胞分化标志物和黑色素瘤亚群。
J Exp Med. 1982 Dec 1;156(6):1755-66. doi: 10.1084/jem.156.6.1755.